Literature DB >> 30037849

Cigarette Smoke-Induced Emphysema Exhausts Early Cytotoxic CD8+ T Cell Responses against Nascent Lung Cancer Cells.

Dimitra Kerdidani1,2, Sophia Magkouta2, Panagiotis Chouvardas1,3, Vassiliki Karavana2, Konstantinos Glynos2, Fani Roumelioti1, Spyros Zakynthinos2, Els Wauters4,5,6, Wim Janssens4,5,6, Diether Lambrechts7,8, George Kollias1,3, Maria Tsoumakidou9.   

Abstract

Chronic obstructive pulmonary disease is a chronic inflammatory disorder with an increased incidence of lung cancer. The emphysema component of chronic obstructive pulmonary disease confers the greatest proportion to lung cancer risk. Although tumors create inflammatory conditions to escape immunity, the immunological responses that control growth of nascent cancer cells in pre-established inflammatory microenvironments are unknown. In this study, we addressed this issue by implanting OVA-expressing cancer cells in the lungs of mice with cigarette smoke-induced emphysema. Emphysema augmented the growth of cancer cells, an effect that was dependent on T cytotoxic cells. OVA-specific OTI T cells showed early signs of exhaustion upon transfer in emphysema tumor hosts that was largely irreversible because sorting, expansion, and adoptive transfer failed to restore their antitumor activity. Increased numbers of PD-L1- and IDO-positive CD11c+ myeloid dendritic cells (DCs) infiltrated emphysema tumors, whereas sorted emphysema tumor DCs poorly stimulated OTI T cells. Upon adoptive transfer in immunocompetent hosts, T cells primed by emphysema tumor DCs were unable to halt tumor growth. DCs exposed to the emphysema tumor microenvironment downregulated MHC class II and costimulatory molecules, whereas they upregulated PD-L1/IDO via oxidative stress-dependent mechanisms. T cell activation increased upon PD-L1 blockade in emphysema DC-T cell cocultures and in emphysema tumor hosts in vivo. Analysis of the transcriptome of primary human lung tumors showed a strong association between computed tomography-based emphysema scoring and downregulation of immunogenic processes. Thus, suppression of adaptive immunity against lung cancer cells links a chronic inflammatory disorder, emphysema, to cancer, with clinical implications for emphysema patients to be considered optimal candidates for cancer immunotherapies.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Year:  2018        PMID: 30037849     DOI: 10.4049/jimmunol.1700700

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Current understanding of the immunosuppressive properties of mesenchymal stromal cells.

Authors:  Ligia Lins de Castro; Miquéias Lopes-Pacheco; Daniel Jay Weiss; Fernanda Ferreira Cruz; Patricia Rieken Macêdo Rocco
Journal:  J Mol Med (Berl)       Date:  2019-03-22       Impact factor: 4.599

2.  Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody.

Authors:  Shijin Yuan; Yan Xia; Lihong Shen; Liuqing Ye; Lisha Li; Lifen Chen; Xinyou Xie; Haizhou Lou; Jun Zhang
Journal:  Cancer Immunol Immunother       Date:  2020-08-27       Impact factor: 6.968

3.  Emphysema assessment for personalized immunotherapy response prediction in lung cancer patients.

Authors:  Dimitra Kerdidani; Sophia Magkouta; Maria Tsoumakidou
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

4.  Quantitative evaluation of emphysema for predicting immunotherapy response in patients with advanced non-small-cell lung cancer.

Authors:  Yoshimi Noda; Takayuki Shiroyama; Kentaro Masuhiro; Saori Amiya; Takatoshi Enomoto; Yuichi Adachi; Reina Hara; Takayuki Niitsu; Yujiro Naito; Kotaro Miyake; Shohei Koyama; Haruhiko Hirata; Izumi Nagatomo; Yoshito Takeda; Atsushi Kumanogoh
Journal:  Sci Rep       Date:  2022-05-25       Impact factor: 4.996

5.  Understanding the mechanisms of immune-evasion by lung cancer in the context of chronic inflammation in emphysema.

Authors:  Ramin Salehi-Rad; Steven M Dubinett
Journal:  J Thorac Dis       Date:  2019-02       Impact factor: 3.005

6.  Immune-mediated genetic pathways resulting in pulmonary function impairment increase lung cancer susceptibility.

Authors:  Linda Kachuri; Mattias Johansson; Sara R Rashkin; Rebecca E Graff; Yohan Bossé; Venkata Manem; Neil E Caporaso; Maria Teresa Landi; David C Christiani; Paolo Vineis; Geoffrey Liu; Ghislaine Scelo; David Zaridze; Sanjay S Shete; Demetrius Albanes; Melinda C Aldrich; Adonina Tardón; Gad Rennert; Chu Chen; Gary E Goodman; Jennifer A Doherty; Heike Bickeböller; John K Field; Michael P Davies; M Dawn Teare; Lambertus A Kiemeney; Stig E Bojesen; Aage Haugen; Shanbeh Zienolddiny; Stephen Lam; Loïc Le Marchand; Iona Cheng; Matthew B Schabath; Eric J Duell; Angeline S Andrew; Jonas Manjer; Philip Lazarus; Susanne Arnold; James D McKay; Nima C Emami; Matthew T Warkentin; Yonathan Brhane; Ma'en Obeidat; Richard M Martin; Caroline Relton; George Davey Smith; Philip C Haycock; Christopher I Amos; Paul Brennan; John S Witte; Rayjean J Hung
Journal:  Nat Commun       Date:  2020-01-07       Impact factor: 14.919

Review 7.  Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis.

Authors:  Jiahang Mo; Xiao Hu; Lihu Gu; Bangsheng Chen; Parikshit Asutosh Khadaroo; Zefeng Shen; Lei Dong; Yuqi Lv; Marylin Nyaradzo Chitumba; Jiequan Liu
Journal:  World J Surg Oncol       Date:  2020-01-20       Impact factor: 2.754

8.  An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer.

Authors:  Panpan Jiang; Ziyang Mao; Qinyang Wang; Xiaohui Jia; Luying Geng; Hong Xu; Lili Jiang; Chengcheng Yang; Min Jiao; Hui Guo
Journal:  Front Oncol       Date:  2021-09-13       Impact factor: 6.244

9.  Systematic Evaluation of Rheumatoid Arthritis Risk by Integrating Lifestyle Factors and Genetic Risk Scores.

Authors:  Xing-Hao Yu; Lin Bo; Rong-Rong Cao; Yi-Qun Yang; Pei He; Shu-Feng Lei; Fei-Yan Deng
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

Review 10.  The Resistance Mechanisms of Lung Cancer Immunotherapy.

Authors:  Fen Wang; Shubin Wang; Qing Zhou
Journal:  Front Oncol       Date:  2020-10-20       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.